RESUMO
Artificial intelligence (AI) holds the promise of addressing many of the numerous challenges healthcare faces, which include a growing burden of illness, an increase in chronic health conditions and disabilities due to aging and epidemiological changes, higher demand for health services, overworked and burned-out clinicians, greater societal expectations, and rising health expenditures. While technological advancements in processing power, memory, storage, and the abundance of data have empowered computers to handle increasingly complex tasks with remarkable success, AI introduces a variety of meaningful risks and challenges. Among these are issues related to accuracy and reliability, bias and equity, errors and accountability, transparency, misuse, and privacy of data. As AI systems continue to rapidly integrate into healthcare settings, it is crucial to recognize the inherent risks they bring. These risks demand careful consideration to ensure the responsible and safe deployment of AI in healthcare.
Assuntos
Inteligência Artificial , Endocrinologia , Humanos , Atenção à Saúde/normas , Endocrinologia/organização & administração , Endocrinologia/tendências , Endocrinologia/métodos , Endocrinologia/normas , Reprodutibilidade dos TestesAssuntos
Endocrinologia , Invenções/tendências , Tumores Neuroendócrinos , Educação Médica/tendências , Endocrinologia/educação , Endocrinologia/métodos , Endocrinologia/tendências , Humanos , Conhecimento , Tumores Neuroendócrinos/diagnóstico , Tumores Neuroendócrinos/etiologia , Tumores Neuroendócrinos/terapiaRESUMO
OBJECTIVE: To evaluate the experience and perceptions of reproductive endocrinology and infertility fellowship applicants and program directors (PDs) regarding the current and future use of web-based interviews (WBIs). DESIGN: Cross-sectional study. SETTING: Nationwide cohort. PATIENT(S): Reproductive endocrinology and infertility fellowship applicants and PDs participating in the 2020 application cycle. INTERVENTION(S): Anonymous survey sent to applicants and PDs. MAIN OUTCOME MEASURE(S): Descriptive study evaluating the experience and satisfaction of applicants and PDs with WBIs. RESULT(S): Forty-six percent of applicants and eligible PDs responded to our survey. Most applicants and PDs responded that WBIs were adequate for conveying a sense of a program's strengths, faculty, diversity, clinical training, and research opportunities, but less than half responded that WBIs were adequate in providing a sense of the program's clinical site and facilities. After WBIs, both applicants (73%) and PDs (86%) were able to rank with confidence. The cost of WBIs was significantly lower for both applicants (median: $100) and programs (median: $100) than the costs previously reported for in-person interviews. The applicants interviewed at more programs than they would have if the interviews were on-site, and Zoom was the highest rated platform used. Most applicants and PDs responded that WBIs were an adequate substitute, and that they should continue after the coronavirus disease 2019 pandemic. Furthermore, most of the PDs were planning to continue to use WBIs in some capacity. CONCLUSION(S): Both applicants and PDs had favorable experiences with and perceptions of WBIs, and most endorse the continued use of this interview modality. The findings of this study can help guide and optimize future WBI practices.
Assuntos
Endocrinologia/organização & administração , Bolsas de Estudo/organização & administração , Entrevistas como Assunto/métodos , Médicos/psicologia , Medicina Reprodutiva/organização & administração , Adulto , COVID-19/epidemiologia , Estudos Transversais , Endocrinologia/educação , Endocrinologia/métodos , Bolsas de Estudo/métodos , Feminino , Humanos , Infertilidade/terapia , Internet , Internato e Residência/métodos , Internato e Residência/organização & administração , Relações Interpessoais , Entrevistas como Assunto/estatística & dados numéricos , Candidatura a Emprego , Masculino , Pessoa de Meia-Idade , Pandemias , Percepção , Satisfação Pessoal , Médicos/estatística & dados numéricos , Medicina Reprodutiva/educação , Medicina Reprodutiva/métodos , SARS-CoV-2 , Estudantes de Medicina/psicologia , Estudantes de Medicina/estatística & dados numéricos , Inquéritos e QuestionáriosRESUMO
BACKGROUND: During the COVID-19 pandemic, telemedicine use rapidly and dramatically increased for management of diabetes mellitus. It is unknown whether access to telemedicine care has been equitable during this time. This study aimed to identify patient-level factors associated with adoption of telemedicine for subspecialty diabetes care during the pandemic. METHODS: We conducted an explanatory sequential mixed-methods study using data from a single academic medical center. We used multivariate logistic regression to explore associations between telemedicine use and demographic factors for patients receiving subspecialty diabetes care between March 19 and June 30, 2020. We then surveyed a sample of patients who received in-person care to understand why these patients did not use telemedicine. RESULTS: Among 1292 patients who received subspecialty diabetes care during the study period, those over age 65 were less likely to use telemedicine (OR: 0.34, 95% CI: 0.22-0.52, P < .001), as were patients with a primary language other than English (OR: 0.53, 95% CI: 0.31-0.91, P = .02), and patients with public insurance (OR: 0.64, 95% CI: 0.49-0.84, P = .001). Perceived quality of care and technological barriers were the most common reasons cited for choosing in-person care during the pandemic. CONCLUSIONS: Our findings suggest that, amidst the COVID-19 pandemic, there have been disparities in telemedicine use by age, language, and insurance for patients with diabetes mellitus. We anticipate telemedicine will continue to be an important care modality for chronic conditions in the years ahead. Significant work must therefore be done to ensure that telemedicine services do not introduce or widen population health disparities.
Assuntos
COVID-19/prevenção & controle , Controle de Doenças Transmissíveis , Diabetes Mellitus/terapia , Disparidades em Assistência à Saúde , Telemedicina , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , COVID-19/epidemiologia , California/epidemiologia , Criança , Pré-Escolar , Controle de Doenças Transmissíveis/métodos , Atenção à Saúde/métodos , Atenção à Saúde/organização & administração , Atenção à Saúde/normas , Atenção à Saúde/estatística & dados numéricos , Diabetes Mellitus/epidemiologia , Diabetes Mellitus Tipo 1/epidemiologia , Diabetes Mellitus Tipo 1/terapia , Diabetes Mellitus Tipo 2/epidemiologia , Diabetes Mellitus Tipo 2/terapia , Endocrinologia/métodos , Endocrinologia/organização & administração , Feminino , Acessibilidade aos Serviços de Saúde/organização & administração , Acessibilidade aos Serviços de Saúde/normas , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Disparidades em Assistência à Saúde/estatística & dados numéricos , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Pandemias , Atenção Primária à Saúde/organização & administração , Atenção Primária à Saúde/normas , Atenção Primária à Saúde/estatística & dados numéricos , Quarentena , SARS-CoV-2 , Telemedicina/organização & administração , Telemedicina/estatística & dados numéricos , Adulto JovemAssuntos
Pé Diabético/diagnóstico , Pé Diabético/terapia , Endocrinologia/tendências , Temperatura Corporal/fisiologia , Análise Custo-Benefício , Pé Diabético/economia , Pé Diabético/epidemiologia , Endocrinologia/métodos , Deformidades Adquiridas do Pé/etiologia , Deformidades Adquiridas do Pé/terapia , Transtornos Neurológicos da Marcha/diagnóstico , Transtornos Neurológicos da Marcha/epidemiologia , Transtornos Neurológicos da Marcha/etiologia , Transtornos Neurológicos da Marcha/terapia , Custos de Cuidados de Saúde , Humanos , Monitorização Fisiológica/métodos , Podiatria/métodos , Podiatria/tendências , Temperatura Cutânea/fisiologiaAssuntos
COVID-19 , Atenção à Saúde , Pandemias , Doenças da Hipófise , COVID-19/complicações , COVID-19/epidemiologia , COVID-19/patologia , COVID-19/terapia , Comorbidade , Atenção à Saúde/métodos , Atenção à Saúde/organização & administração , Atenção à Saúde/tendências , Endocrinologia/métodos , Endocrinologia/organização & administração , Endocrinologia/tendências , História do Século XXI , Humanos , Pandemias/história , Doenças da Hipófise/complicações , Doenças da Hipófise/epidemiologia , Doenças da Hipófise/terapia , Fatores de Risco , SARS-CoV-2/fisiologia , Índice de Gravidade de DoençaAssuntos
Pé Diabético , Amputação Cirúrgica , Procedimentos Clínicos/organização & administração , Procedimentos Clínicos/normas , Desbridamento/métodos , Desbridamento/normas , Atenção à Saúde/organização & administração , Atenção à Saúde/normas , Angiopatias Diabéticas/epidemiologia , Angiopatias Diabéticas/etiologia , Angiopatias Diabéticas/terapia , Pé Diabético/diagnóstico , Pé Diabético/epidemiologia , Pé Diabético/etiologia , Pé Diabético/terapia , Técnicas de Diagnóstico Endócrino/normas , Endocrinologia/métodos , Endocrinologia/organização & administração , Endocrinologia/normas , Alemanha/epidemiologia , Pessoal de Saúde/organização & administração , Pessoal de Saúde/normas , Humanos , Procedimentos Ortopédicos/métodos , Procedimentos Ortopédicos/normas , Medicina Preventiva/métodos , Medicina Preventiva/normas , Fatores de RiscoRESUMO
Assessment and management of children with growth failure has improved greatly over recent years. However, there remains a strong potential for further improvements by using novel digital techniques. A panel of experts discussed developments in digitalization of a number of important tools used by pediatric endocrinologists at the third 360° European Meeting on Growth and Endocrine Disorders, funded by Merck KGaA, Germany, and this review is based on those discussions. It was reported that electronic monitoring and new algorithms have been devised that are providing more sensitive referral for short stature. In addition, computer programs have improved ways in which diagnoses are coded for use by various groups including healthcare providers and government health systems. Innovative cranial imaging techniques have been devised that are considered safer than using gadolinium contrast agents and are also more sensitive and accurate. Deep-learning neural networks are changing the way that bone age and bone health are assessed, which are more objective than standard methodologies. Models for prediction of growth response to growth hormone (GH) treatment are being improved by applying novel artificial intelligence methods that can identify non-linear and linear factors that relate to response, providing more accurate predictions. Determination and interpretation of insulin-like growth factor-1 (IGF-1) levels are becoming more standardized and consistent, for evaluation across different patient groups, and computer-learning models indicate that baseline IGF-1 standard deviation score is among the most important indicators of GH therapy response. While physicians involved in child growth and treatment of disorders resulting in growth failure need to be aware of, and keep abreast of, these latest developments, treatment decisions and management should continue to be based on clinical decisions. New digital technologies and advancements in the field should be aimed at improving clinical decisions, making greater standardization of assessment and facilitating patient-centered approaches.
Assuntos
Inteligência Artificial , Nanismo/diagnóstico , Endocrinologia/métodos , Hormônio do Crescimento Humano , Pediatria/métodos , Criança , Hormônio do Crescimento Humano/análise , Hormônio do Crescimento Humano/uso terapêutico , HumanosAssuntos
Infecções por Coronavirus/epidemiologia , Diabetes Mellitus Tipo 1/terapia , Diabetes Mellitus Tipo 2/terapia , Pneumonia Viral/epidemiologia , Telemedicina/métodos , COVID-19 , Controle de Doenças Transmissíveis , Diabetes Mellitus Tipo 1/epidemiologia , Diabetes Mellitus Tipo 2/epidemiologia , Educação a Distância , Endocrinologia/métodos , Endocrinologia/tendências , Havaí/epidemiologia , Acessibilidade aos Serviços de Saúde , Pessoas Mal Alojadas , Humanos , Seguro Saúde , Medicaid , Medicare , Pandemias , Médicos , Estados Unidos , Comunicação por VideoconferênciaRESUMO
Background: The 2015 American Thyroid Association (ATA) clinical practice guidelines (CPGs) on management of thyroid nodules (TNs) and differentiated thyroid cancer (DTC) in adults were developed to inform clinicians, patients, researchers, and health policy makers about the best available evidence, and its limitations, relating to management of these conditions. Methods: We conducted a cross-sectional electronic survey of ATA members' perspectives of these CPGs, using a standardized survey (Clinician Guidelines Determinant Questionnaire) developed by the Guidelines International Network. A survey link was electronically mailed to members in February of 2019, with reminders sent to nonrespondents 2 and 5 weeks later. Data were descriptively summarized, after excluding missing responses. Results: The overall response rate was 19.8% (348/1761). The effective response rate was 20.2% (348/1720), after excluding a recently deceased member and individuals who had either invalid e-mail addresses or whose e-mails were returned. Of the respondents, 37.9% (132/348) were female, 60.4% (209/346) were endocrinologists, 27.5% (95/346) were surgeons, and 3.5% (12/346) were nuclear medicine specialists. The majority of respondents (71.9%; 250/348) were at a mid- or advanced-career level, and more than half were in academia (57.5%; 195/339). The majority (69.8%; 243/348) practiced in North America. The vast majority of respondents indicated that the CPGs explained the underlying evidence (92.3%; 298/323) and 92.9% (300/323) agreed or strongly agreed with the content. Most respondents stated that they regularly used the CPGs in their practice (83.0%; 268/323). Most respondents (83.0%; 268/323) also agreed or strongly agreed that the recommendations were easy to incorporate in their practice. The most popular CPG format was an electronic desktop file (78.8%; 252/320). Shorter more frequent CPGs were favored by 55.0% (176/320) of respondents, and longer traditional CPGs were favored by 39.7% (127/320). Conclusions: The clinical content and evidence explanations in the adult TN and DTC CPGs are widely accepted and applied among ATA survey respondents. Future ATA CPG updates need to be optimized to best meet users' preferences regarding format, frequency, and length.
Assuntos
Endocrinologia/normas , Guias de Prática Clínica como Assunto , Neoplasias da Glândula Tireoide/diagnóstico , Nódulo da Glândula Tireoide/diagnóstico , Adulto , Diferenciação Celular , Estudos Transversais , Endocrinologia/métodos , Feminino , Política de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Sociedades Médicas , Cirurgiões , Inquéritos e Questionários , Estados UnidosRESUMO
The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Assuntos
Complicações do Diabetes/diagnóstico , Complicações do Diabetes/epidemiologia , Diabetes Mellitus/epidemiologia , Técnicas de Diagnóstico Endócrino/normas , Comorbidade , Complicações do Diabetes/terapia , Diabetes Mellitus/terapia , Endocrinologia/história , Endocrinologia/métodos , Endocrinologia/organização & administração , Endocrinologia/normas , História do Século XXI , Humanos , Padrões de Referência , Sociedades Médicas/normas , Padrão de Cuidado/normas , Estados Unidos/epidemiologiaRESUMO
The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Assuntos
Diabetes Mellitus/terapia , Invenções/normas , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/métodos , Automonitorização da Glicemia/tendências , Diabetes Mellitus/sangue , Diabetes Mellitus/epidemiologia , Endocrinologia/instrumentação , Endocrinologia/métodos , Endocrinologia/organização & administração , Endocrinologia/normas , Equipamentos e Provisões/normas , História do Século XXI , Humanos , Insulina/administração & dosagem , Sistemas de Infusão de Insulina/normas , Invenções/história , Invenções/tendências , Padrões de Referência , Sociedades Médicas/organização & administração , Sociedades Médicas/normas , Padrão de Cuidado/história , Padrão de Cuidado/normas , Estados Unidos/epidemiologiaRESUMO
OBJECTIVE: We conducted a systematic review of studies evaluating the cost-effectiveness (CE) of interventions to prevent type 2 diabetes (T2D) among high-risk individuals and whole populations. RESEARCH DESIGN AND METHODS: Interventions targeting high-risk individuals are those that identify people at high risk of developing T2D and then treat them with either lifestyle or metformin interventions. Population-based prevention strategies are those that focus on the whole population regardless of the level of risk, creating public health impact through policy implementation, campaigns, and other environmental strategies. We systematically searched seven electronic databases for studies published in English between 2008 and 2017. We grouped lifestyle interventions targeting high-risk individuals by delivery method and personnel type. We used the median incremental cost-effectiveness ratio (ICER), measured in cost per quality-adjusted life year (QALY) or cost saved to measure the CE of interventions. We used the $50,000/QALY threshold to determine whether an intervention was cost-effective or not. ICERs are reported in 2017 U.S. dollars. RESULTS: Our review included 39 studies: 28 on interventions targeting high-risk individuals and 11 targeting whole populations. Both lifestyle and metformin interventions in high-risk individuals were cost-effective from a health care system or a societal perspective, with median ICERs of $12,510/QALY and $17,089/QALY, respectively, compared with no intervention. Among lifestyle interventions, those that followed a Diabetes Prevention Program (DPP) curriculum had a median ICER of $6,212/QALY, while those that did not follow a DPP curriculum had a median ICER of $13,228/QALY. Compared with lifestyle interventions delivered one-on-one or by a health professional, those offered in a group setting or provided by a combination of health professionals and lay health workers had lower ICERs. Among population-based interventions, taxing sugar-sweetened beverages was cost-saving from both the health care system and governmental perspectives. Evaluations of other population-based interventions-including fruit and vegetable subsidies, community-based education programs, and modifications to the built environment-showed inconsistent results. CONCLUSIONS: Most of the T2D prevention interventions included in our review were found to be either cost-effective or cost-saving. Our findings may help decision makers set priorities and allocate resources for T2D prevention in real-world settings.
Assuntos
Diabetes Mellitus Tipo 2/prevenção & controle , Estado Pré-Diabético/economia , Estado Pré-Diabético/terapia , Medicina Preventiva/economia , Medicina Preventiva/métodos , Adulto , Idoso , Redes Comunitárias/economia , Redes Comunitárias/organização & administração , Redes Comunitárias/estatística & dados numéricos , Análise Custo-Benefício , Diabetes Mellitus Tipo 2/economia , Diabetes Mellitus Tipo 2/epidemiologia , Endocrinologia/economia , Endocrinologia/métodos , Endocrinologia/tendências , Custos de Cuidados de Saúde , Gastos em Saúde/estatística & dados numéricos , Promoção da Saúde/economia , Promoção da Saúde/métodos , Promoção da Saúde/estatística & dados numéricos , Humanos , Estilo de Vida , Metformina/uso terapêutico , Pessoa de Meia-Idade , Educação de Pacientes como Assunto/economia , Educação de Pacientes como Assunto/organização & administração , Educação de Pacientes como Assunto/estatística & dados numéricos , Vigilância da População/métodos , Estado Pré-Diabético/epidemiologia , Anos de Vida Ajustados por Qualidade de Vida , Fatores de Risco , Comportamento de Redução do Risco , Adulto JovemRESUMO
OBJECTIVE: To synthesize updated evidence on the cost-effectiveness (CE) of interventions to manage diabetes, its complications, and comorbidities. RESEARCH DESIGN AND METHODS: We conducted a systematic literature review of studies from high-income countries evaluating the CE of diabetes management interventions recommended by the American Diabetes Association (ADA) and published in English between June 2008 and July 2017. We also incorporated studies from a previous CE review from the period 1985-2008. We classified the interventions based on their strength of evidence (strong, supportive, or uncertain) and levels of CE: cost-saving (more health benefit at a lower cost), very cost-effective (≤$25,000 per life year gained [LYG] or quality-adjusted life year [QALY]), cost-effective ($25,001-$50,000 per LYG or QALY), marginally cost-effective ($50,001-$100,000 per LYG or QALY), or not cost-effective (>$100,000 per LYG or QALY). Costs were measured in 2017 U.S. dollars. RESULTS: Seventy-three new studies met our inclusion criteria. These were combined with 49 studies from the previous review to yield 122 studies over the period 1985-2017. A large majority of the ADA-recommended interventions remain cost-effective. Specifically, we found strong evidence that the following ADA-recommended interventions are cost-saving or very cost-effective: In the cost-saving category are 1) ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB) therapy for intensive hypertension management compared with standard hypertension management, 2) ACEI/ARB therapy to prevent chronic kidney disease and/or end-stage renal disease in people with albuminuria compared with no ACEI/ARB therapy, 3) comprehensive foot care and patient education to prevent and treat foot ulcers among those at moderate/high risk of developing foot ulcers, 4) telemedicine for diabetic retinopathy screening compared with office screening, and 5) bariatric surgery compared with no surgery for individuals with type 2 diabetes (T2D) and obesity (BMI ≥30 kg/m2). In the very cost-effective category are 1) intensive glycemic management (targeting A1C <7%) compared with conventional glycemic management (targeting an A1C level of 8-10%) for individuals with newly diagnosed T2D, 2) multicomponent interventions (involving behavior change/education and pharmacological therapy targeting hyperglycemia, hypertension, dyslipidemia, microalbuminuria, nephropathy/retinopathy, secondary prevention of cardiovascular disease with aspirin) compared with usual care, 3) statin therapy compared with no statin therapy for individuals with T2D and history of cardiovascular disease, 4) diabetes self-management education and support compared with usual care, 5) T2D screening every 3 years starting at age 45 years compared with no screening, 6) integrated, patient-centered care compared with usual care, 7) smoking cessation compared with no smoking cessation, 8) daily aspirin use as primary prevention for cardiovascular complications compared with usual care, 9) self-monitoring of blood glucose three times per day compared with once per day among those using insulin, 10) intensive glycemic management compared with conventional insulin therapy for T2D among adults aged ≥50 years, and 11) collaborative care for depression compared with usual care. CONCLUSIONS: Complementing professional treatment recommendations, our systematic review provides an updated understanding of the potential value of interventions to manage diabetes and its complications and can assist clinicians and payers in prioritizing interventions and health care resources.
Assuntos
Diabetes Mellitus/economia , Diabetes Mellitus/terapia , Endocrinologia/tendências , Prática Clínica Baseada em Evidências/tendências , Padrões de Prática Médica/tendências , Adulto , Idoso , Idoso de 80 Anos ou mais , Comorbidade , Análise Custo-Benefício , Complicações do Diabetes/economia , Complicações do Diabetes/epidemiologia , Complicações do Diabetes/terapia , Diabetes Mellitus/epidemiologia , Endocrinologia/história , Endocrinologia/métodos , Prática Clínica Baseada em Evidências/história , Feminino , História do Século XX , História do Século XXI , Humanos , Masculino , Programas de Rastreamento/economia , Programas de Rastreamento/história , Programas de Rastreamento/métodos , Programas de Rastreamento/tendências , Pessoa de Meia-Idade , Padrões de Prática Médica/história , Padrões de Prática Médica/estatística & dados numéricos , Gravidez , Anos de Vida Ajustados por Qualidade de Vida , Telemedicina/economia , Telemedicina/tendênciasRESUMO
INTRODUCTION: No study has been published to date in Spain about the value of the American Thyroid Association (ATA) ultrasound risk assessment of thyroid nodules applied by endocrinologists. OBJECTIVES: To assess the diagnostic performance of ATA thyroid nodule risk classification applied by endocrinologists with respect to histological results. METHODS: A retrospective, observational study of 317 patients (mean age, 51.7±13.7 years; 83.3% women) with thyroid nodules (maximum diameter: 3.2±1.4cm) who underwent US-guided FNA in endocrinology between October 2015 and December 2018, were classified based on the ATA ultrasound risk assessment. Surgery was performed in all of them. Quality criteria of the ultrasound classification were assessed as compared to histological results. RESULTS: Overall, 61.2% of nodules assessed were classified as benign (n=3) and very low (n=60) or low suspicion (n=131), 11.7% as intermediate suspicion (n=37), and 27.1% as high suspicion (n=86). Benign nodular disease was found in 260 patients, and thyroid cancer in 57 patients. There were 14 incidental papillary microcarcinomas. Classification of thyroid nodules as high suspicion showed a high diagnostic performance to identify malignant nodules (87.7% sensitivity, 86.2% specificity, negative predictive value 97.0%), improving sensitivity (93.0%) and reducing specificity (73.1%) when considering high and intermediate suspicion nodules as a risk for thyroid cancer. CONCLUSIONS: Application by endocrinologists of the ATA ultrasound risk assessment of thyroid nodules shows a high diagnostic performance to identify malignant thyroid nodules before surgery.
Assuntos
Medição de Risco/métodos , Nódulo da Glândula Tireoide/diagnóstico por imagem , Adulto , Endocrinologia/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudos Retrospectivos , Neoplasias da Glândula Tireoide/diagnóstico por imagem , Neoplasias da Glândula Tireoide/epidemiologia , Nódulo da Glândula Tireoide/classificação , Nódulo da Glândula Tireoide/epidemiologia , UltrassonografiaAssuntos
Efeitos Psicossociais da Doença , Fibrose Cística , Educação/métodos , Endocrinologia/métodos , Doenças Metabólicas , Qualidade de Vida , Comorbidade , Fibrose Cística/epidemiologia , Fibrose Cística/psicologia , Fibrose Cística/terapia , Educação Médica Continuada/organização & administração , Educação Médica Continuada/tendências , Humanos , Expectativa de Vida , Doenças Metabólicas/classificação , Doenças Metabólicas/epidemiologia , Doenças Metabólicas/terapia , Administração dos Cuidados ao Paciente/métodos , Administração dos Cuidados ao Paciente/tendências , Equipe de Assistência ao Paciente , Análise de SobrevidaRESUMO
BACKGROUND: In recent randomized clinical trials, an unusual reporting pattern of glycemic data and hypoglycemic events potentially related to an internet enabled blood glucose meter (MyGlucoHealth, BGM) was observed. Therefore, this clinical study was conducted to evaluate the system accuracy of the BGM in accordance with the ISO15197:2015 guidelines with additional data collection. METHODS: To investigate system accuracy, 10 of 3088 devices and 6 of 23 strip lots, used in the trials, were selected by a randomization procedure and a standard repeatability assessment. YSI 2300 STAT Plus was used as the standard reference method. The samples were distributed as per the ISO15197:2015 recommendations with 20 additional samples in the hypoglycemic range. Each sample was tested with 6 devices and 6 strip lots with double determinations. RESULTS: Overall, 121 subjects with blood glucose values 26-423 mg/dL were analyzed, resulting in 1452 data points. In all, 186/1452 readings (12.8%) did not meet the ISO acceptance criteria. Data evaluated according to the FDA guidelines showed that 336/1452 (23.1%) readings did not meet the acceptance criteria. A clear bias toward elevated values was observed for BG <100 mg/dL (MARD: 11.0%). CONCLUSIONS: The results show that the BGM, although approved according to standard regulatory guidelines, did not meet the level of analytical accuracy required for clinical treatment decisions according to ISO 15197:2015 and FDA requirements. In general, caution should be exercised before selection of BGMs for patients and in clinical trials.
Assuntos
Glicemia/análise , Diabetes Mellitus/sangue , Hipoglicemia/diagnóstico , Acesso à Internet , Ensaios Clínicos Controlados Aleatórios como Assunto , Tecnologia sem Fio/instrumentação , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/normas , Ensaios Clínicos como Assunto , Coleta de Dados/instrumentação , Coleta de Dados/normas , Endocrinologia/instrumentação , Endocrinologia/métodos , Endocrinologia/normas , Desenho de Equipamento/normas , Análise de Falha de Equipamento , Feminino , Humanos , Hipoglicemia/sangue , Hipoglicemia/epidemiologia , Masculino , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Ensaios Clínicos Controlados Aleatórios como Assunto/normas , Ensaios Clínicos Controlados Aleatórios como Assunto/estatística & dados numéricos , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Tecnologia sem Fio/normasRESUMO
Members of the College of Physicians and Surgeons of Ontario Endocrinology and Metabolism Peer Review Network have been involved in a quality improvement project to help standardize the peer assessment of physicians practicing in endocrinology and metabolism. This has included developing state-of-the-art summaries of common endocrine problems by Canadian experts in endocrinology and metabolism. These tools have been developed in response to the educational needs, as identified by peer reviewers, of practicing endocrinologists in Ontario. These pedagogical tools aim not only to standardize the documentation of the clinical performance of endocrinologists but also to make the process more transparent and to improve the quality of patient care in Ontario. This article summarizes the project and also provides the tools developed for the endocrinology and metabolism section of the College of Physicians and Surgeons of Ontario.